Preliminary results from the Primary Rituximab and Maintenance (PRIMA) phase III trial showed that patients with follicular lymphoma who continued to take rituximab monotherapy as maintenance therapy after responding to an initial course of rituximab plus chemotherapy experienced longer progression-free survival (PFS) than did those who did not receive rituximab maintenance. Because this PFS benefit was evident at a planned interim analysis by the study’s independent data and safety monitoring board,...